EHA 2022 | An update on SWOG 1318: blinatumomab followed by POMP maintenance in older patients with Ph-ALL

Name: An update on SWOG 1318: blinatumomab followed by POMP maintenance in older patients with Ph-ALL
Uploaded: 2022-06-12T00:00:00Z
Duration: 1 min 43 s
Description: Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the SWOG 1318 study (NCT02143414), commenting on the results of the GIMEMA LAL2116 trial (NCT02744768). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Harry Erba • 12 Jun 2022

EHA 2022

Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib

GIMEMA LAL2116 SWOG 1318

Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the SWOG 1318 study (NCT02143414), commenting on the results of the GIMEMA LAL2116 trial (NCT02744768). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.